Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07830719 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 33 days later Sep 16, 2027 → Oct 19, 2027
See other at-risk trials from Novartis

Record History

  1. Recruitment opened Primary and study completion pushed from Sep 16, 2027 to Oct 19, 2027 · Start date changed from estimate of Nov 9, 2026 to Sep 18, 2026 · Study sites: 0 to 1 Show 3 more changesShow less
    • Primary and study completion pushed from Sep 16, 2027 to Oct 19, 2027
    • Start date changed from estimate of Nov 9, 2026 to Sep 18, 2026
    • Study sites: 0 to 1
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
Coronary Artery Disease
1,538 trials monitored
See 68 trials at risk
The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and residual inflammatory risk defined by elevated high-sensitivity C-reactive protein (hsCRP) (≥2 mg/L)
Trial Details
NCT Number NCT07830719
Lead Sponsor Novartis Pharmaceuticals
Conditions Coronary Artery Disease
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov